TY - JOUR
T1 - Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries)
AU - Vesikari, Timo
AU - Itzler, Robbin
AU - Matson, David O.
AU - Santosham, Mathuram
AU - Christie, Celia D.C.
AU - Coia, Michele
AU - Cook, John R.
AU - Koch, Gary
AU - Heaton, Penny
N1 - Funding Information:
Dr. Matson is a grant recipient from NIH, Merck, and
PY - 2007/12
Y1 - 2007/12
N2 - Objective: To evaluate the effect of a human-bovine reassortant pentavalent rotavirus vaccine (PRV) on health care encounters in nearly 70 000 subjects randomized in three regions - Europe, the United States, and Latin America/the Caribbean - in the Rotavirus Efficacy and Safety Trial (REST). Methods: Healthy 6- to 12-week-old infants received 3 doses of PRV or placebo at 4- to 10-week intervals. The exact binomial method for ratios of Poisson counts was used to evaluate the effect of PRV on the rate of rotavirus-related hospitalizations and emergency department (ED) visits involving rotavirus G-types 1-4 occurring ≥14 days after the third dose of vaccine for up to 2 years. Results: In fully vaccinated infants, reductions in rotavirus-associated hospitalizations and ED visits were 94.7% (95% CI: 90.9, 96.9) in Europe, 94.9% (95% CI: 84.0, 98.9) in the United States, and 90.0% (95% CI: 29.4, 99.8) in the Latin American/Caribbean regions. Conclusions: PRV reduced hospitalizations and ED visits within each region in REST. Results were consistent across regions and across the overall study cohort.
AB - Objective: To evaluate the effect of a human-bovine reassortant pentavalent rotavirus vaccine (PRV) on health care encounters in nearly 70 000 subjects randomized in three regions - Europe, the United States, and Latin America/the Caribbean - in the Rotavirus Efficacy and Safety Trial (REST). Methods: Healthy 6- to 12-week-old infants received 3 doses of PRV or placebo at 4- to 10-week intervals. The exact binomial method for ratios of Poisson counts was used to evaluate the effect of PRV on the rate of rotavirus-related hospitalizations and emergency department (ED) visits involving rotavirus G-types 1-4 occurring ≥14 days after the third dose of vaccine for up to 2 years. Results: In fully vaccinated infants, reductions in rotavirus-associated hospitalizations and ED visits were 94.7% (95% CI: 90.9, 96.9) in Europe, 94.9% (95% CI: 84.0, 98.9) in the United States, and 90.0% (95% CI: 29.4, 99.8) in the Latin American/Caribbean regions. Conclusions: PRV reduced hospitalizations and ED visits within each region in REST. Results were consistent across regions and across the overall study cohort.
KW - Emergency department
KW - Health care utilization
KW - Hospitalizations
KW - Human-bovine reassortant pentavalent rotavirus vaccine
KW - Rotavirus
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=37349059999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=37349059999&partnerID=8YFLogxK
U2 - 10.1016/S1201-9712(07)60019-8
DO - 10.1016/S1201-9712(07)60019-8
M3 - Review article
C2 - 18162243
AN - SCOPUS:37349059999
VL - 11
SP - S29-S35
JO - International Journal of Infectious Diseases
JF - International Journal of Infectious Diseases
SN - 1201-9712
IS - SUPPL. 2
ER -